Manufacturing Challenges & Considerations for Allogeneic Cell Therapy
Hanson Wade Intelligence
The allogeneic cell therapy space has many development and manufacturing bottlenecks which are further compounded by the diversity of cell types, delivery systems and gene editing technologies that are now being pursued in the clinic.
To better elucidate these challenges Hanson Wade Intelligence, our Market Research division, spoke to 15 key opinion leaders within the allogeneic cell therapy space. We summarised their views alongside quantitative insights from our Beacon Adoptive Cell database in this opinion review.
This report aims to provide cell therapy developers with valuable insights on the main allogeneic manufacturing challenges and considerations for optimisation of key stages of development.
Clinical Development of the Allogeneic
PBCAR T Cells: Evaluating Persistence and
Investigating its Correlation with Efficacy
Chris Heery, M.D.
Chief Medical Officer, Precision BioSciences Inc.
Workshop G: Enhancing Immune Infiltration
in the Solid Tumor
Construct and Target Selection
Alessandra Cesano MD PhD
Franco Marincola MD
Introducing DAR-T Technology and Non-Viral Vector Manufacturing
Wenzhong Guo, CTO, Cell Therapy
Sorrento Therapeutics Inc
WHAT’S ON OUR READING LIST FOR THE HOLIDAYS?